Patents by Inventor Charles E. Chase

Charles E. Chase has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180162885
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Inventors: Atsushi ENDO, Charles E. CHASE, Francis G. FANG
  • Publication number: 20180118755
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Application
    Filed: May 9, 2016
    Publication date: May 3, 2018
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE
  • Publication number: 20180037588
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Application
    Filed: October 18, 2017
    Publication date: February 8, 2018
    Inventors: Charles E. CHASE, Atsushi ENDO, Francis G. FANG, Jing LI
  • Publication number: 20180002342
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 4, 2018
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • Patent number: 9856276
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: January 2, 2018
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Atsushi Endo, Charles E. Chase, Francis G. Fang
  • Patent number: 9802953
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 31, 2017
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • Patent number: 9783549
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: October 10, 2017
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • Patent number: 9604993
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 28, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Charles E. Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • Publication number: 20160376294
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Application
    Filed: June 29, 2016
    Publication date: December 29, 2016
    Inventors: Atsushi ENDO, Charles E. CHASE, Francis G. FANG
  • Publication number: 20160264594
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: November 4, 2014
    Publication date: September 15, 2016
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • Publication number: 20160214992
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 28, 2016
    Inventors: Charles E. CHASE, Atsushi ENDO, Francis G. FANG, Jing LI
  • Patent number: 9382262
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 5, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Charles E. Chase, Francis G. Fang
  • Patent number: 9303050
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: April 5, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Farid Benayoud, Trevor Lee Calkins, Charles E. Chase, William Christ
  • Publication number: 20150232490
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Application
    Filed: February 17, 2015
    Publication date: August 20, 2015
    Inventors: Farid Benayoud, Trevor Lee Calkins, Charles E. Chase, William Christ
  • Publication number: 20150225415
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Application
    Filed: February 17, 2015
    Publication date: August 13, 2015
    Inventors: Charles E. CHASE, Atsushi ENDO, Francis G. FANG, Jing LI
  • Publication number: 20150175620
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Inventors: Atsushi ENDO, Charles E. CHASE, Francis G. FANG
  • Patent number: 8927597
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: January 6, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Charles E. Chase, Francis G. Fang
  • Patent number: 8884031
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: November 11, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Charles E. Chase, Francis G. Fang
  • Patent number: RE45324
    Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: January 6, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Brian Austad, Charles E. Chase, Francis G. Fang
  • Patent number: RE46965
    Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: July 24, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Brian Austad, Charles E. Chase, Francis G. Fang, Trevor Calkins, Bryan M. Lewis